



Rapid Dose Therapeutics Corp.

Management's Discussion and Analysis

May 31, 2024

MANAGEMENT'S DISCUSSION AND ANALYSIS

This Management's Discussion and Analysis ("MD&A") provides discussion and analysis of the financial condition and results of operations of Rapid Dose Therapeutics Corp. (the "Company") for the three-month period May 31, 2024 and should be read in conjunction with the audited Consolidated Financial Statements and the accompanying notes which have been prepared in accordance with International Financial Reporting Standards.

The MD&A is the responsibility of management and is dated as of July 26, 2024.

All dollar amounts in the MD&A are stated in Canadian dollars unless otherwise indicated.

Additional information relating to the Company is available on SEDAR at www.sedar.com and the Company's website at www.rapid-dose.com.

Forward-Looking Statements

Certain statements in this MD&A August contain "forward-looking information," within the meaning of applicable securities laws, including the "safe harbour provisions" of the Securities Act (Ontario) with respect to the Company. Such statements include, but are not limited to, statements with respect to expectations, projections or other characterizations of future events or circumstances, and our objectives, goals, strategies, beliefs, intentions, plans, estimates, projections and outlook, including statements relating to our plans and objectives, or estimates or predictions of actions of customers, suppliers, competitors or regulatory authorities. These statements are subject to certain risks, assumptions and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. The words "believe", "plan", "intend", "estimate", "expect", "anticipate" and similar expressions, as well as future or conditional verbs such as "will", "should", "would" and "could" often identify forward-looking statements. We have based these forward-looking statements on our current views with respect to future events and financial performance. With respect to forward-looking statements contained in this MD&A, the Company has made assumptions and applied certain factors regarding, among other things: future product pricing; costs of inputs; its ability to market products successfully to its anticipated clients; reliance on key personnel; regulatory requirements; the application of federal and state environmental laws; and the impact of increasing competition. These forward-looking statements are also subject to the risks and uncertainties discussed in the "Risks Factors" section of the CSE Listing Statement as filed on SEDAR and elsewhere in this MD&A and other risks detailed from time to time in the publicly filed disclosure documents of the Company which are available at www.sedar.com and on the Company's website at www.rapid-dose.com. Forward-looking statements are not a guarantee of future performance and involve risks, uncertainties and assumptions which could cause actual results to differ materially from the conclusions, forecasts or projections anticipated in these forward-looking statements. Because of these risks, uncertainties and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this MD&A and, except as required by applicable law, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new information, future events or circumstances.

See page 18 for Material assumptions and risk factors for forward-looking statements.

The Company

The Company is a public Canadian life-sciences corporation that provides innovative, proprietary, drug-delivery technologies designed to improve outcomes and quality of lives. The Company owns a proprietary oral fast-dissolving drug delivery system, QuickStrip™, which is capable of rapidly releasing into the blood stream a list of pharmaceuticals, emulsified oils and over-the-counter medicines without being degraded or modified by first pass metabolism in the liver. The Company also provides product innovation, production and consultation to the nutraceutical, cannabis healthcare and pharmaceutical manufacturing industries.

The Company is a reporting issuer in Ontario, Alberta and British Columbia and its common shares are listed for trading on the Canadian Securities Exchange ("CSE") under the trading symbol "DOSE".

The Company is incorporated under the laws of Ontario. Its head office and registered office is located at 1121 Walker's Line, Unit 3A, Burlington, Ontario, L7N 2G4.

Business Overview

For the three-month period ended May 31, 2024, the Company recognized revenue of \$ 398,994 (May 31, 2023 - \$ 240,787) and incurred a net comprehensive loss of \$1,256,851 (May 31, 2023 - \$ 566,881). Expenses during the year, amounting to \$1,514,990 (May 31, 2024 - \$684,486) included the non-cash charge for personnel costs of \$ 426,700 (May 31, 2024 - \$nil) for stock-based compensation for stock options issued under the Company's share option plan. Other non-cash charges were accretion expense of \$135,975 and depreciation of \$82,733 (May 31, 2023 - 146,512 including right of use amortization). The Company expects losses to continue in the near term as it completes the final stages of its preparations for global product launches in nutraceuticals, pharmaceuticals, cannabis and vaccines.

As at May 31, 2024, the Company had a working capital deficiency of \$2,183,722 (May 31, 2023 - \$2,239,314) and an accumulated deficit of \$40,511,984 (May 31, 2023 - \$35,534,436).

The continued operation of the Company is dependent on the support of its creditors and the Company's ability to secure advances from related parties and debt and equity financing to meet its existing obligations and finance its operations.

Social Responsibility

The Company fosters an environment of social responsibility in every aspect of the business which promotes tolerance, acceptance and care of People, Products and the Planet. The Company remains committed to discovering ways to mitigate excess packaging (within the regulations), reduce overall waste, and find environmental solutions that align with its mission to make an impactful difference in the lives of its customers. As the Company's plan for the introduction of new Cannabis 2.0 regulated products and non-regulated Hemp topical lotions continue to evolve, research into the various packaging methods has been successful in developing novel formats that encourage environmental responsibility. The Company also continues to reinforce the concept of a remote, flexible workplace, which allows each team member to function from their remote locations and limit face to face meetings to respond to the pandemic safety measures as well as commit to reducing our carbon footprint in as many ways as possible.

Micro Processing Licence

Product approvals

On May 13, 2024, the Company received its Health Canada cannabis site license renewal for its Burlington, Ontario facility. The Excise Tax license renewal was granted concurrently.

The facilities lease expired on March 31, 2024 and has been replaced by a lease amendment extending through to August 31, 2024 under the same terms and conditions of the expired lease. Thereafter the Company may continue to lease the facility under the terms of the lease amendment agreement until February 28, 2025. The Company has applied the practical expedient and did not capitalize the lease.

In June 2023, the Company received approval from the Ontario Cannabis Stores for two products to be sold through the OCS retail and on-line channels, commencing in the fall of 2023.

In November 2022, the Company received its sales renewal licence from Health Canada enabling the Company to sell its cannabis products to the Canadian recreational market through the provincial retail distribution channels. Sales of products are anticipated to commence in November 2022 once provincial requirements for packaging, volumes and delivery are confirmed. The sales licence enables the Company to sell directly to the Canadian provincial distributors for the recreational cannabis market where the product is not otherwise distributed by Cannmart.

On February 21, 2022, the Company received the renewal of its excise tax licence granted by the Canada Revenue Agency. The excise tax licence will allow the Company to accept delivery of cannabis oil from its customers for the production of QuickStrip™ which will be delivered back to the customers.

In July 2021 the Company was audited by the Cannabis Directorate of Health Canada for the purpose of obtaining a full cannabis sales licence. The follow-on Inspection Report issued August 13th 2021 contained no major or critical observations.

On November 15, 2019, the Company was granted a micro-processing licence by Health Canada for its Burlington, Ontario facility in accordance with the Cannabis Act and Cannabis Regulations. The micro-processing licence will enable the Company to produce cannabis infused QuickStrip™ products for the Canadian market under manufacturing agreements with Canadian licensed producers.

Manufacturing Agreements

The Company manufactures private label QuickStrip™ products for the Canadian market at its facilities located in Burlington, Ontario.

The Company has manufacturing agreements with the following companies:

Licensed Producer	Date of agreement	Term	Products	Territory
Thrive Cannabis	August 8, 2019	5 years	CBD and THC products for medical and recreational markets	Canada
Tweed/Canopy Growth	April 2024	2 years	CBD and THC products for medical and recreational markets	Canada

Thrive (Aurora)

The Company produces CBD and THC QuickStrip™ products for Thrive which have been introduced by Thrive throughout Canada into the recreational cannabis market commencing in January 2021 QuickStrip produced products are sold by Thrive under the “Being” brand.

Tweed/Canopy Growth

The Company began production CBD and THC QuickStrip™ products for Tweed in April 2024 with the first delivery of products in May 2024.

Abba Medix-MTL Cannabis

Abba Nedix is a Medical Cannabis Company that serves veterans and first responders. They support life after service by providing best in class medical Cannabis Products

Mendo

Mendo is a Medical Cannabis company with the widest selection of products from across Canada and the highest quality compassionate care to patients who truly need it. We understand that for many, pain is a daily part of life and that nobody should have to live in pain when there are treatments available. Medical Cannabis has many medical benefits that ease the pain that traditional medicine cannot offer. Mendo’s focus is to provide a safe environment for patients to receive treatment using Medical Cannabis.

Kinhana

Kin Hana Artisan Craft Cannabis is a medical company focusing on the intersection between cultivation, education and wellness

Distributor agreements

The Company entered into several supply and sales agreements during the Fiscal Year 2024. These agreements provide opportunities to sell the Company’s existing nutraceutical products in Canada and the United Kingdom and cannabis products throughout the Canadian provinces. In addition, the agreements provide the subsidiary, CCB, with distributors for existing and developing product portfolios.

Distributor	Date of agreement	Term	Territory
ANCAR Canada Limited	May 2, 2021	3 years	Canada and United States

ANCAR has developed a convenience store retail channel for nutraceutical products.

Oakland Health	May 26, 2021	3 years	United Kingdom
----------------	--------------	---------	----------------

Oakland Health is developing a retail chain presence in the UK offering a suite of the Company’s products. Oakland Health initiated the application for approval of the Company’s CBD from hemp product with the FSA under the Novel Foods Act. The application was submitted in March 2020 and is still in the approval process.

In March 2022 the Company filed for approval of its CBD strip from hemp products with the UK Food Standards Agency (FSA), meeting the deadline for submission for a validated Novel Food application (NFA). Brands that are not compliant with the Novel Foods Regime will be removed from shelves according to the FSA. The Novel Foods process is costly and time consuming. The application remains under examination by the regulatory body.

UK Oakland Sales Development

Oakland Health, our local UK partners, operating as RD Therapeutics, have selected a minimum of 4 products to launch into the UK market. These products underwent formulation modifications and packaging changes to address consumer requirements in the UK market. These changes delayed the initial launch timeline and revenue projections due to global supply chain issues. Market-test products have been produced, shipped, and rolled out in the UK to gauge receptivity by consumers and retailers. Oakland has set an online strategy to reach consumers and demonstrate the benefits of carrying the products for consumers on their shelves. There is no anticipated additional expense to RDT to generate revenue in this market.

COVID mRNA Vaccine QuickStrip

The company continues the ongoing research with the oral delivery of the COVID vaccine without the need for cold-chain logistics, we have established a relationship with pharmaceutical companies with a global scope who have developed a vaccine and want to investigate the QuickStrip delivery format. Revenue for the R&D by RDT will be generated as a fee for service with strategic pharmaceutical partners and through application of government funding grants similar to the IRAP grants received in fiscal years 2021 and 2022.

The additional expenditures for the submission of IP to the USPO or other jurisdictions is budgeted as an annual expenditure of \$300,000. In addition, the Company has contracted for services of \$225,000 annually for project management and the development of pharmaceutical relationships. The costs of testing are funded by and is the responsibility of strategic pharmaceutical partners who own the vaccines.

Key players in the UK associated with the WHO and the global pandemic preparedness group 100 Days Mission are aware of the RDT delivery platform and are supportive of its continued development.

Skycare Compounders - Pharmaceutical Drug Development

Subsequent to the signing of the collaboration agreement with Skycare Compounding in April 21, 2022, the Company and Skycare have been working on the development of products for the medical and dental industry. The pharmaceutical products will be produced in Skycare's compounding facility operated by Skycare using RDT's equipment and production processes under a revenue sharing agreement.

The company has completed the setup and installed the equipment at Skycare's Licensed compounding facility to produce multiple pharmaceutical products for the medical market including Dental products. Product development has been completed and the products will be distributed and sold to Dental Clinic's, Doctors' Offices, Hospitals and Pharmacy's. The major expenditures have been completed including years of Research & Development, facility & production setup, equipment installation, training, packaging development & design, Certificates of Analysis, Standard Operating procedures, product testing, website development, marketing trials and sales contract agreements in process for sales. Skycare is responsible for the manufacturing, sales and distribution under the agreement.

Dental Market

In the dental segment, the Company announced the successful launch of two initial dental products, Xylitol and Lidocaine strips. The "Xylitol" solution addresses "dry mouth", a serious health condition affecting greater than 25% of the North American population. Over \$3.0B per annum is spent on dry mouth treatments in Canada. "Lidocaine" is an alternative pain therapy which manages pain and replaces other pain therapy solutions during dental procedures.

These products were showcased at the Ontario Dental Association convention and the Quebec Dental Association convention. where dental professionals experienced their benefits firsthand. Xylitol and Lidocaine strips are now available to dental offices and pharmacies nationwide through RDT's trusted distributors, Henry Schein and Skycare.

Nicotine

In the nicotine segment, the Company has entered into a research and development ("R&D") project in collaboration with one of the world's largest tobacco manufacturers. The objective is to develop a new nicotine product, complete with flavoring and packaging. The Company anticipates submitting an FDA approval application

for the US market by the fall of 2024. Furthermore, the Company's tobacco collaborator has engaged a third-party marketing firm to create a comprehensive global forecast. Additionally, a human nicotine trial involving 24 patients is being conducted to evaluate its impact on heart health in comparison to other nicotine products. RDT's focus will be manufacturing and "R&D". The nicotine market is significant as currently there are over 20.0 billion cigarettes being consumed daily on a global basis, and the Company's channel partner is one of the industry's largest players.

Pharmaceutical

In the pharmaceutical segment, the Company is in the process of launching Tadalafil and Sildenafil (generic versions of Cialis and Viagra), both proven erectile dysfunction molecules. These products will be available to doctors, pharmacies, and hospitals. The opportunity in addressing erectile dysfunction is a significant market opportunity. It affects approximately 40% of men by age 40 and nearly 70% by age 70. In 2021, the global market was estimated to be approximately US\$2.296 billion growing at over 8% per annum. RDT is committed to making a substantial impact in this field.

Vaccines

In the vaccine segment, the Company has initiated a research project with a large pharmaceutical company to integrate their vaccines into RDT's strips. Additionally, the Company is collaborating with a US-based vaccine provider to load their Plasma DNA vaccines onto RDT's strips. Furthermore, the Company is partnering with a US-based university to research the ability to infuse a Fentanyl vaccine into the QuickStrip. This particular vaccine is a unique offering which addresses the growing opioid addiction crisis in North America by curtailing the drug craving. The advantages of sublingual strip technology in the vaccine market are potentially extensive and include:

- Eliminating the need for needles.
- Eliminating the need for cold chain or reconstitution.
- Eliminating the need for qualified health care professional administration.
- Precise and reproducible dosing.
- Cost savings at government and local levels.

Nutraceuticals

The Company's nutraceutical products are currently available in over 378 "Circle K" locations, and grocery retailers with more than 500 locations, including multiple independent stores and "Relay" stores at airports as well as through online e-commerce channels. This distribution network ensures that consumers have convenient access to the Company's nutraceutical products across various retail channels. RDT has more than 40 nutraceutical formularies available on its sublingual strips.

Company in conjunction with McMaster University received the award of a Mitacs Accelerate grant, with a value of \$30,000 in May 2024 in addition to \$55,000 in 2023, to continue the development of Thin Polymer Films for Vaccine Delivery Project, led by Prof. Alex Adronov, of McMaster University. This grant-funded research project aims to support further formulation development and proof of-concept studies to develop the capability to vaccinate individuals leveraging RDT's QuickStrip™ Oral Thin Film ("OTF") technology.

Previously, the initial phase of research led by Prof. Alex Adronov had demonstrated that the RDT QuickStrip™ technology is effective at encapsulating and releasing biomolecules and m-RNA loaded lipid nanoparticles. The current funding aims to advance this work by demonstrating mRNA transfection to living cells, where mRNA delivery is made possible by RDT's QuickStrip™ technology. This work will pave the way for buccal or sublingual vaccine delivery, eliminating the need for costly and unpleasant intramuscular injections. In addition, investigation of thermal stability of active ingredients within the OTF is underway, which will help alleviate the need for cold-chain storage and transport of these delivery constructs. The project has further evolved to study a variety of biomolecules where formulation optimization and various proof of concept experiments, both in vitro and in vivo, are under way.

Clinical Study

May 29, 2024 – Company in collaboration in the National Football League (NFL) – funded clinical trial program entitled "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports" led by Dr. J. Patrick Neary and researchers at the University of Regina. RDT will partake in a randomized, two-arm clinical study, which is part of a larger clinical program designed by an expert team of cerebrovascular and neurophysiologists, clinical psychologists, pharmacokineticists, and physicians from the Universities of Regina, Saskatchewan, and British Columbia.

The primary research objective of the study is to determine the relative oral bioavailability and other pharmacokinetic (PK) parameters of the non-psychoactive cannabidiol (CBD) and its metabolites, when administered to a healthy young adult population as RDT's sublingual QuickStrip™ product, versus a standard oral formulation.

The data generated from this study will demonstrate the efficacy of the QuickStrip™ product and serve as the basis for including RDT's QuickStrip™ in the subsequent clinical studies as part of the overall clinical program funded by the NFL. "This study has the potential to change not only the lives of current and former NFL players, but also the lives of anyone who may suffer from a concussion," said Dr. Patrick Neary, exercise physiologist and professor in the Faculty of Kinesiology and Health Studies at the University of Regina.

May 22, 2024, The Company in partnership with McMaster University ("McMaster") demonstrated the results of their collaborative research project titled "Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Film Strips. Loratadine, sold under the brand name Claritin, among others, is an antihistamine commonly used to treat allergic rhinitis. It undergoes liver first pass metabolism and is a prime candidate for incorporation within an OTF.

This research project enabled RDT to advance its formulation capabilities by successfully utilizing a method that increases the solubility of the commonly used drug loratadine, allowing it to be effectively loaded into the QuickStrip™ delivery platform.

Collaborative Research

In May 2021, the Company, McMaster University and the National Research Council (NRC) entered into a three-way material transfer agreement which provided the research team at McMaster University in early June 2021 with the Covid-19 spike protein in sufficient quantities to enable animal testing of the QuickStrip™ infused with the spike protein for the purpose of determining the capabilities of developing antibodies from this vaccine delivery method. The COVID pandemic has provided a unique opportunity for the Company to exploit their flagship QuickStrip™ technology as an efficient and effective vaccine delivery method for a variety of viruses including COVID, SARS, Ebola, Yellow Fever and Malaria. The use of the QuickStrip™ simplifies the logistics challenges of delivering vaccines to the world's most remote communities by eliminating the cost and access to freezer storage and eliminating the requirement to allocate health care professionals for administering needles. The Company is confident that suitable partners in the pharmaceutical industry will be anxious to test infusing their own vaccine formulations into the QuickStrip™ format.

The Company is continuing to develop its commercialization opportunities during the testing phases to ensure that, with successful outcomes, the Company is prepared to execute a go to market plan that covers the shortest possible timelines within the constraints of the regulatory processes for applying and approving a vaccine delivery alternative.

On July 21, 2020, the Company announced the commencement of COVID-19 vaccine research in conjunction with McMaster University and the team lead by Drs. Alex Adronov, James Mahony and Mark Larché. The federally funded project tests the use of QuickStrip™ for administering vaccines orally as a convenient and safe alternative to injection with needles, the currently accepted delivery format for most vaccines.

On June 19, 2020, the Company filed a non-provisional patent with the USPTO for an "Apparatus for and method of converting CBD and/or CBD derivatives to at least one other type of cannabinoid and/or cannabinoid derivative such as THC". In conjunction with McMaster University and the team led by Dr. James McNulty, RDT has discovered a new and efficient way to create THC from CBD. The project's research has continued on subsequent to the non-provisional patent filing with continuing input from the Company's science research team. These patent applications have been registered in Canada, the United States and in Europe.

On February 4, 2020, the Company secured government funding of \$400,000 from The National Research Council of Canada Industrial Research Assistance to support a project focused on commercial development and scale-up manufacturing of cannabis infused QuickStrip™ oral dissolvable film strips. The funding helped the Company to augment product commercialization by enhancing its manufacturing competency while creating new jobs and training skilled technical employees. The Company received \$200,000 of its grant funding in the fiscal year ended February 28, 2021 and the final \$200,000 in the fiscal year ended February 28, 2022.

On January 23, 2020, the Company announced a new research partnership program entitled "Rapid Delivery of Therapeutics via Dissolution of Polymeric Films" with [McMaster University](#), located in Hamilton, Ontario, Canada.

The project focuses on developing novel biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films. This research program has been awarded a NSERC Collaborative Research and Development grant by the Natural Sciences and Engineering Research Council of Canada. The project is being administered in conjunction with the vaccine project as a secondary funding source for the McMaster research team.

Share capital

Authorized

An unlimited number of common shares without par value.

Common Shares

As at July 26, 2024, the Company had 124,636,166 common shares outstanding. (February 29, 2024 – 117,810,298 common shares outstanding),

A summary of the capitalization is provided as follows:

Common shares	124,636,166
Warrants	29,166,393
Options	11,550,000
Fully Diluted	165,352,559

Financial transactions

- (i) On July 19, 2024 the Company closed on \$309,000 in the first tranche of its previously announced private placement financing, through the issue of 1,817,647 of common shares at \$0.17 per share. The Financing contemplates up to \$6,000,000 of gross proceeds, through the issue of common shares at a price of \$0.17 per Unit.
- (ii) On May 16, 2024 the Company closed on \$250,000 in a fifth tranche of its previously announced private placement financing, through the issue of 1,470,586 of common share units at \$0.17 per share bringing the total amount raised to \$1,960,000. Each Unit consisted of one (1) common share of the Company (a “**Common Share**”) and one (1) common share purchase warrant of the Company (a “**Warrant**”). Each Warrant is exercisable to acquire one (1) Common Share at a price of \$0.20 per Common Share for a term of two (2) years from the date of issuance of such Warrant. On this fifth tranche closing of the Financing, 1,470,586 Units were purchased; and accordingly, the Company issued 1,470,586 Common Shares and 1,470,586 Warrants.
- (iii) On April 15, 2024 the Company closed on \$300,000 in a fourth tranche of its previously announced private placement financing through the issue of 1,764,704 of common share units at \$0.17 per share.
- (iv) On April 3, 2024 the Company closed on \$110,000 in a third tranche of its previously announced private placement financing through the issue of 647,059 of common share units at \$0.17 per share.
- (v) On April 1, 2024 the Company issued 9,050,000 stock options with an exercise price of \$0.18 per common share expiring April 1, 2026
- (vi) On March 31, 2024 the Company issued 562,936 common shares for interest owing on convertible notes at \$0.18 per shares and issued 41,553 common shares for interest owing on the related party loan.
- (vii) On February 28, 2024 the Company cancelled 5,350,000 out of the money stock options, re-issued as part of the grant of stock options on April 1, 2024
- (viii) On February 23, 2024 the Company issued 2,500,000 stock options to directors at an exercise price of \$0.15 per common shares expiring February 23, 2026;

- (ix) On February 23, 2024 the Company closed on \$200,000 in a second tranche of its previously announced private placement financing through the issue of 1,176,470 of common share units at \$0.17 per share;
- (x) On February 16, 2024 the Company closed on \$1,100,000 in a first tranche of its previously announced private placement financing through the issue of 6,470,586 of common share units at \$0.17 per share;
- (xi) On January 15, 2024 the Company issued 4,349,457 of common shares in settlement of \$699,813 of unpaid vendor liabilities;
- (xii) On December 31, 2023 the Company issued 798,942 common shares for interest and fees owing on convertible notes;
- (xiii) On December 22, 2023 the Company issued \$855,000 of secured convertible notes together with 4,275,000 of warrants at an exercise price of \$0.14 expiring November 20, 2025, in a fourth tranche closing of the announced convertible notes private placement financing;
- (xiv) On November 14, 2023 the Company issued \$500,000 of secured convertible notes together with 2,500,000 warrants in a third tranche closing of the announced convertible notes private placement financing;
- (xv) On September 30, 2023 the Company issued 2,040,888 common shares for interest and fees owing on convertible notes and issued 132,397 of common shares for interest and fees owing on the related party loan;
- (xvi) On September 22, 2023 the Company issued \$310,000 of secured convertible notes together with 1,550,000 of warrants in a second tranche closing of the announced convertible notes private placement financing;
- (xvii) On July 21, 2023 the Company issued \$1,469,445 of secured convertible notes together with 7,347,225 of warrants, expiring on November 30, 2025 in the first tranche closing in accordance with the terms of the convertible note private financing agreement;
- (xviii) On May 26, 2022, the Company closed a private placement financing which raised \$151,847 through the issuance of 506,157 common share units at a price of \$0.30 per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant is entitled to acquire one common share at a price of \$0.4 per common share for twenty-four months from the date of issuance;
- (xix) On January 5, 2022 200,000 share purchase options were issued at \$0.51 per share vesting semi-annually over two years and expiring on January 5, 2027;
- (xx) On December 15, 2021, 500,000 share purchase options were issued at \$0.58 per share vesting semi-annually over two years and expiring on December 15, 2026;
- (xxi) During the quarter ended November 30, 2021 520,437 warrants were exercised in exchange for one common share for each warrant at a price of \$0.375 per common share. A further 153,000 warrants were exercised in exchange for one common share at a price of \$0.21 per common share and 200,000 warrants were exercised in exchange for one common share at a price of \$0.40 per common share. Total proceeds from the issuance of 873,437 common shares amounted to \$307,294;
- (xxii) During the quarter ended August 31 2021, 1,966,000 warrants were exercised in exchange for one common share for each warrant at a price of \$0.375 per common share. A further 55,000 warrants were exercised in exchange for one common share at a price of \$0.21 per common share;
- (xxiii) During the quarter ended August 31 2021, 1,966,000 warrants were exercised in exchange for one common share for each warrant at a price of \$0.375 per common share. A further 55,000 warrants were exercised in exchange for one common share at a price of \$0.21 per common share;
- (xxiv) On March 29, 2021, the Company granted 4,490,000 stock options under the Company's stock option plan to certain directors, officers, employees and consultants, with each option entitling the holder to purchase one common share for \$0.24 until March 28, 2024. The options shall vest in four semi-annual

increments of 25% commencing September 28, 2021;

- (xxv) On March 19, 2021, 20,000,000 common share units were issued (each, a “Unit”) pursuant to a business combination by way of a three-cornered amalgamation between the Company, 2814882 Ontario Inc., a wholly owned subsidiary of the Company, (Subco”) and 2544737 Ontario Limited, o/a Consolidated Craft Brands, (“CCB”) which closed on March 19, 2022. Each Unit is comprised of one common shares of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”) of the Company, each such Warrant entitling the holder thereof to acquire one Common Share at a price of \$0.375 per Common Share at any time on or before March 19, 2024 (note 10). These options expired on March 28, 2024;
- (xxvi) On December 16, 2020, the Company completed a non-brokered private placement of 3,599,370 common shares at a price of \$0.25 per common share unit for gross proceeds of \$899,843. In connection with the private placement, the Company paid a finder’s fee of \$87,150 and issued 3,599,370 warrants with each warrant entitling the holder to purchase one common share for \$0.40 per common share until December 16, 2022. These options expired on December 16, 2022;
- (xxvii) On October 9, 2019 and October 30, 2019, the Company completed tranches of a non-brokered private placement of 1,276,108 common shares at a price of \$0.70 per common share for gross proceeds of \$893,276. Of the common shares issued, 227,857 common shares were issued to two directors and officers of the Company. In connection with the private placement, the Company paid a finder’s fee of \$35,369 and issued 17,684 warrants with each warrant entitling the holder to purchase one common share for \$1.00 per common share until October 9, 2021. These options expired on October 9, 2021.

Stock options

The Company adopted a stock option plan under which it can grant options to directors, officers, employees, and consultants for up to 10% of the issued and outstanding common shares. Under the plan, the exercise price of an option may not be less than the closing market price during the trading day immediately preceding the date of the grant of the option, less any applicable discount allowed by the Canadian Securities Exchange.

On April 1, 2024 the Company granted 9,050,000 stock options to employees and advisors, at \$0.18 per share, vesting in accordance with the Company’s Stock Option Plan policy, expiring twenty-four months from the date of issue. On April 1, 2024, the Company issued 9,050,000 to employees and company consultants at an exercise price of \$0.18 per shares expiring on April 1, 2026. On issue, twenty-five (25%) percent of the options were vested, with further vesting of twenty-five (25%) of the options vested every six months until fully vested on October 1, 2025. Options granted to officers of the Company totaled 4,350,000 options.

During the year ended February 29, 2024, options amounting to 2,500,000 were issued on February 23, 2024 at \$0.15 per share, vesting in accordance with the Company’s Stock Option Plan policy, expiring twenty-four months from the date of issue.

On February 28, 2024, the Company’s remaining 5,350,000 stock options were cancelled and replaced on April 1, 2024 at \$0.18 per share, vesting in accordance with the Company’s Stock Option Plan policy, expiring twenty-four months from the date of issue.

There were no options issued in 2023.

A summary of the Company's outstanding stock options as at February 29, 2024 is presented below:

	Weighted Ave (“\$”)	Number of Options	Contributed surplus
Balance, February 28, 2022	0.54	10,281,000	4,146,322
Cancelled	0.24 to 0.82	(1,176,250)	-
Share based compensation	0.24	-	706,931
Balance, February 29, 2023	0.56	9,104,750	4,853,253
Expired	0.375	(3,754,750)	-
Extinguishment	-	-	(17,202)
Share based compensation	-	-	162,249
Cancelled February 28, 2024	0.24	(5,350,000)	-
Fair valuation of convertible notes	-	-	245,726
Issued, February 23, 2024	0.15	2,500,000	-
Balance, February 29, 2024		2,500,000	5,244,026

Issued April 1 2024	0.18	9,050,000	426,699
Balance, May 31, 2024		11,550,000	5,670,726

Warrants

A summary of the continuity of warrant activity is as follows:

	Weighted average price	Number of warrants	Warrant reserve
			\$
Balance, February 29, 2023		16,813,838	2,299,675
Expired and extinguished	\$0.40	(16,284,681)	(1,720)
Issued – secured convertible note	\$0.14	15,672,225	1,291,732
Issued – September 2023	\$0.14	1,250,000	48,486
Issued – private placement (ii)	\$0.20	7,647,035	530,134
Issued – issuance cost	\$0.20	458,823	55,646
Balance, February 29, 2024		25,557,240	4,223,953
Expired and extinguished	\$0.40	(506,157)	-
Issued – private placement (i)	\$0.20	4,115,289	28,1247
Balance, May 31, 2024		29,166,393	4,505,200

Included in the issued warrants above are warrants issued to directors of the Company amounting to 9,371,855 in connection with the issue of their secured convertible notes and related party debt.

Brokers' Warrants

- (i) On April 3, April 15 and May 15, 2024 the Company closed three tranches of private placement financing and issued 3,882,349 warrants to the subscribers of the units and issued 232,940 brokers' warrants in accordance with the terms of the private placement offering. The warrants may be exercised at the price of \$0.20 per share expiring on the second anniversary date of the issuance of the warrants.
- (ii) On February 23 and 16, 2024 the Company closed two tranches of private placement financing and issued brokers' warrants of 458,823 in accordance with the terms of the private placement offering. The warrants may be exercised at the price of \$0.20 per share expiring on the second anniversary date of the issuance of the warrants.
- (iii) On January 19, 2022, the Company recorded 200,000 Warrants in its accounts pursuant to the services agreement with the investment adviser. The Warrants have a two-year term and are exercisable during that term at \$0.33 each; As at the reporting date, the 200,000 warrants remain unissued.
- (iv) On June 3, 2021, the Company issued a further 200,000 Warrants pursuant to the same advisory agreement as in (i) above, having a two-year term and exercisable during that term at \$0.21 each. These warrants were exercised during the fiscal year ended February 28, 2024.
- (v) On March 29 2021, the Company issued 200,000 Warrants pursuant to a Public Relations Services Agreement having a two-year term and exercisable during that term at \$0.24 each. These warrants expired on March 29, 2024
- (vi) On March 28 2021, pursuant to an Advisory Agreement, the Company issued 200,000 Warrants having a two-year term and exercisable during that term at \$0.21 each. These warrants were exercised during the fiscal year ended February 28, 2022.

Convertible notes private placement financing

Unsecured convertible notes

The Company closed a private placement of unsecured convertible notes (each a “Note”) for gross proceeds of \$230,000 on August 8, 2022 (the “Offering”). The Company issued 230 units where each unit consisted of \$1,000 principal amount of Notes and 100 common share purchase warrants. The Notes, issued in increments of \$1,000, bear interest at a rate of 12% per annum, have a term of twenty-four (24) months from the date of issue and are convertible into common shares at a conversion price of \$0.40 per share. Each Warrant is exercisable into one Common Share of the Company at an exercise price of \$0.40 per Common Share for a period of twenty-four (24) months from the date of issuance of the Notes. Securities issued pursuant to the Offering are subject to a statutory hold period lasting four (4) months and a day after the issuance of the securities. The Company paid issuance costs of \$28,955, of which \$4,184 was allocated to the equity component of the issuances.

The Notes bear Interest from their date of issue at 10.0% per annum, payable quarterly in arrears. A further 2% per annum interest payment will be made annually in cash or in Common Shares as determined by the Company. During the second year of the two-year term of the Notes, the Company may prepay all or any portion of each of the Notes with an early termination fee payable to each noteholder of one percent (1%) per annum of the amount of the principal prepayment of the Notes.

The fair value of the warrants and conversion feature was estimated as \$3,021 and \$30,211 respectively, with reference to Black-Scholes pricing model with the following assumptions: (i) expected dividend yield of 0%; (ii) expected volatility of 387.33%; (iii) risk-free rate of 3.23%; (iv) share price of \$0.085; (v) forfeiture rate of nil; (vi) expected life of two years.

The fair value of the liability component at issuance was calculated as the discounted cash flows for the 2022 convertible note assuming a market interest rate of 22%, which was the estimated rate without the equity component of the conversion feature. The effective interest rate of the 2022 unsecured convertible note after reflecting issuance costs was 20%.

During the year ended February 29, 2024, the Company has recalled convertible notes of \$130,000 and issued two secured convertible notes for the amount of the notes and accrued interest thereon. The secured convertible notes have substantially different terms and since there has been a substantial modification of the terms of the existing financial liability, these transactions have been accounted for as an extinguishment of the original financial liability and the recognition of the new financial liability.

As at February 28, 2024, the principal amount of \$100,000 is outstanding and due on August 8, 2024.

The following provides a summary of the changes to the unsecured notes obligations as at May 31, 2024:

	Notes	Warrants	Conversion Feature	Total
	\$	\$	\$	\$
Balance, February 28, 2022	-	-	-	-
Issuance of convertible notes, net of issuance costs	171,997	3,021	30,211	205,229
Accretion of notes	14,960	-	-	14,960
Balance, February 28, 2023	186,957	3,021	30,211	220,189
Accretion of noted	17,482	-	-	17,482
Extinguishment of liability	(111,077)	(1,720)	(17,202)	(129,999)
Balance, February 29, 2024	93,362	1,301	12,909	107,672
Accretion of notes	3,824	-	-	3,824
Balance, May 31, 2024	97,186	1,301	12,909	111,496

Secured convertible notes

During the year, the Company issued secured convertible notes (“Secured Convertible notes”) in exchange for gross cash proceeds of \$1,935,000, bearing interest of 12% per annum, payable quarterly, payable in common shares of the Company. The holders of the Secured Convertible Notes may convert the principal amount into shares of the Company at a price of \$0.17 per share, with a maturity date of November 30, 2025.

The Company settled \$1,199,445 of unsecured debt through the issuance of secured convertible notes. The secured convertible notes have substantially different terms and since there has been a substantial modification of the terms of the existing financial liabilities, these transactions have been accounted for as an extinguishment of the original financial liabilities and the recognition of new financial liabilities.

In connection with the issuance of the Secured Convertible Notes, the Company paid \$156,722 for debt issuance fees through the issuance of 1,300,326 common shares and legal fees of 109,390. The Company recorded interest expense of \$99,295 (payable in shares of 740,522) and accretion expense of \$142,914 for the year ended February 29, 2024.

At the subscription of the Secured Convertible Notes, each investor was also issued 5 warrant “Warrant Shares” to be utilized for the future purchase of shares of the Company. The total number of Subscription Warrants issued was 15,672,225. The holders of the Warrant Shares convert the principal amount into shares of the Company at a price of \$0.14 per share. These Subscription Warrants were issued based on the original amount invested into the Secured Convertible Notes. The expiry of the Subscription Warrants is November 30, 2025.

The Company used the Black-Scholes option-pricing model to estimate fair value of the embedded warrant and conversion feature of loan. The inputs used by management to determine the fair value are the expected future volatility in the price of the Company’s shares and the expected life of the Secured Convertible Notes.

The conversion features, embedded warrants require a fixed number of shares to settle, therefore, they meet the criteria of fixed to fixed under IFRS, and hence classified as equity. Accordingly, the fair values of these were deducted from the gross proceeds and were accreted over the term of the note.

The Company may prepay the Notes in certain circumstances. During the period from June 30, 2024, to December 31, 2024, the Company shall be entitled to prepay all or any portion of each of the Notes with a prepayment fee payable to each noteholder of 3% of the amount of the principal prepayment of the Note. There shall be no prepayment fee if the Notes are repaid after December 31, 2024. The Notes are secured pursuant to a general security agreement issued by the Company in favour of the various noteholders.

The following range of assumptions were used to value the equity components during the period ended February 29, 2024.

Volatility: 120% to 145%

Risk-free interest rate: 3.22% to 4.02%

Expected life (years): 1.94 to 2.36 years.

Share price: \$0.11 to 0.17.

Exercise price: \$0.14 - \$0.17

A reconciliation of the secured convertible notes payable for the three-month period ended, 2024, is as follows:

	Notes	Warrants	Conversion Feature	Total
	\$	\$	\$	\$
Balance, February 28, 2023	-	-	-	-
Issuance of convertible notes, net of issuance costs	1,981,960	1,291,732	245,726	3,519,418
Accretion of notes	142,914	-	-	142,914
Balance, February 28, 2024	2,124,874	1,291,732	245,726	3,662,332
Accretion of notes	121,223	-	-	121,223
Balance, May 31, 2024	2,246,097	1,291,732	245,726	3,883,555

Accounts payable and accrued liabilities

	February 29, 2024	February 28, 2023
	\$	\$
Accounts payable	1,121,128	1,408,771
Accrued liabilities	1,468,317	1,372,174
	<u>2,589,445</u>	<u>2,780,945</u>

Included in the accounts payable is \$12,000 owed to an officer/director of the Company. Unpaid wages for officers of the Company of \$100,000 are included in accrued liabilities.

Related party transactions

Related parties include the members of the Board of Directors, key management personnel, and any companies controlled by these individuals. Key management personnel include those persons having authority and responsibility for planning, directing, and controlling activities of the Company, namely Directors, Chief Executive Officer, Chief Financial Officer, and Senior Vice President, Business Development.

Related party debt

Due to a related party represents unsecured advances from an individual who is an officer and director of the Company and a secured loan from a company controlled by a director of the Company.

	February 29, 2024	February 28, 2023
	\$	\$
Promissory note, interest at 12% per annum, payable monthly, due April 1, 2024	-	253,000
Promissory note, non- interest bearing, due April 1, 2024	-	109,000
Promissory note, interest at 12% per annum, payable monthly, due March 1, 2024	-	150,000
Convertible loan, interest at 12% per annum, payable quarterly, September 22, 2024	229,216	-
	<u>229,216</u>	<u>512,000</u>

On July 21, 2023, \$500,000 of the related party debt was rolled into convertible notes. The balance of the notes of \$12,000 and accrued interest is due on demand has been accrued and included in Accounts payable and accrued liabilities.

As consideration for the exchange of the notes, the director/officer received 2,500,000 warrants which may be converted into 2,500,000 common shares at an exercise price of \$0.14 expiring on November 30, 2025. In addition, the director/officer received a fee of five percent (5%) of the value of the notes paid in common shares at the trading price of the shares of the Company at that date.

The secured debt loan of (\$250,000) was taken over by a related party. As part of the agreement to assume the debt obligation, the loan maturity date was extended to September 22, 2024. In exchange the Company issued 1,250,000 warrants to the related party. Each warrant may be exercised for one Common Share at a price of \$0.14, for a one-year term. The Company paid a loan fee of \$12,500 to the related party by issuing 125,000 Common Shares on October 13, 2023, at the trading price of the shares of the Company at that date. Interest on the Debt is 12.0% per annum calculated monthly, compounded, accrued, added to the principal amount and payable in common shares, quarterly in arrears on a calendar quarter basis until the Debt is fully repaid.

During the year, the Company issued 7,400 Common Shares to the related party at a deemed issue price of \$0.10 per Common Share and 46,291 Common Shares at a deemed issue price of \$0.165 per Common Share against interest of \$8,378 for secured promissory note.

A summary of the transaction for the related party loan for the year ended February 29, 2024, is as follows:

	Notes	Warrants	Total
	\$	\$	\$
Balance, February 28, 2023	-	-	-
Loan proceeds, net of issuance costs	179,262	48,486	227,748
Accretion of notes	27,026	-	27,026
Balance, February 28, 2024	206,288	48,486	254,774
Accretion of notes	121,223	-	121,223
Balance, May 31, 2024	327,511	48,486	375,997

Transactions with related parties

On January 15, 2024, Peter Thilo-Hasler received 138,612 common shares in exchange for \$22,178 of consulting services provided to the Company during the fiscal year (2023 - \$Nil)

During the year, the Company issued total gross proceeds of \$1,696,371 of secured convertible notes. This includes conversion of a related party loan from an officer/director of the Company of \$500,000. The remaining notes payable of \$12,000 have been included in accounts payable and accrued liabilities and remains unpaid as at June 28, 2024.

There is a receivable of \$18,992 from a director of the Company. The Company received the amount subsequent to year end.

A director of the Company assumed the debt obligation of \$250,000, through a company controlled by the director, to retire a third-party debt obligation which matured on July 5, 2023. The debt amendment and issuance of the 1,250,000 warrants and payment of the \$12,500 loan fee indirectly to John McKimm (via his holding company, Madison Partners Corporation), a director of the Company, is a related party transaction within the meaning of MI 61-101.

The Company issued stock options to non-management directors on February 23, 2024. The Company has recorded stock-based compensation of \$87,374 to the directors of the Company in its accounts as at February 29, 2024.

Compensation of key management personnel

Key management personnel includes those persons having the authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. Key management personnel comprise the directors, executive and non-executive and officers.

The following table sets out the total value of compensation provided to Officers of the Company:

	Three-month period ended May 31 2024			Three-month period ended May 31 2023		
	Salaries	Stock-based compensation	Total	Salaries	Stock-based compensation	Total
Officers	\$	\$	\$	\$	\$	\$
Mark Upsdell, for his services as Chief Executive Officer	37,500	63,946	101,446	37,500	-	37,500
Jason Lewis, for his services as Senior Vice President, Business Development	37,500	61,814	99,314	37,500	-	37,500
Douglas Hyland, for his services as Interim CFO	37,500	46,893	84,393	37,500	-	37,500
	<u>112,500</u>	<u>172,653</u>	<u>285,153</u>	<u>112,500</u>	<u>-</u>	<u>112,500</u>

The following table sets out the unpaid compensation to Officers at May 31, 2024

Mark Upsdell	\$50,000
Douglas Hyland	<u>56,250</u>
	\$ 106,250

The following table sets out compensation to Directors for options received on February 23, 2024:

Directors	Stock-based compensation
	\$
John McKimm	23,575
Peter Thilo-Hasler	37,719
Christine Hrudka	23,575
Marisa Cornacchia	23,575
Angela O'Leary	23,575
	<u>70,724</u>

Effective June 1, 2024, each Director who is independent will be paid a director fee of \$10,000 per quarter, which fee may be paid in shares of the Company at the end of each quarter at the then current market price.

Interest paid to officer and directors

During the three-month period ended May 31, 2024 the Company paid interest to officers, directors and related companies of the directors in common shares as follows:

	Interest paid	Common shares issued
	\$	
Mark Upsdell	14,959	83,105
John McKimm/Madison Corp Partners	10,362	57,567
Angela O'Leary	23,934	132,968

Christine Hrudka	1,496	8,310
Interest paid to related parties	50,751	281,950

Material assumptions and risk factors for forward-looking statements

The following table outlines certain forward-looking statements contained in this MD&A and provides material assumptions used to develop such forward-looking statements and material risk factors that could cause actual results to differ materially from the forward-looking statements.

Forward-looking statement	Assumption	Risk factor
Liquidity and Capital Resources "Management is of the opinion that sufficient working capital will be obtained from advances from related parties and equity financings to meet the Company's liabilities and commitments as they become due."	Advances from related parties and equity financings will be obtained and such advances and financings will be in sufficient amounts to meet the Company's liabilities and commitments as they come due.	The Company is unable to obtain future financing to meet its liabilities and commitments as they become due.

Risks and Uncertainties

There are numerous and varied risks, known and unknown, that may prevent the Company from achieving its goals. If any of these risks occur, the Company's business, financial condition or results of operation August be adversely affected.

Limited operating history

Because the Company has a limited operating history and is in an emerging area of business, investors should consider and evaluate its operating prospects in light of the risks and uncertainties frequently encountered by early-stage companies in rapidly evolving markets. These risks may include:

- risks that it may not have sufficient capital to achieve its growth strategy;
- risks that it may not develop its product and service offerings in a manner that enables it to be profitable and meet its customers' requirements;
- risks that its growth strategy may not be successful;
- risks that fluctuations in its operating results will be significant relative to its revenues;
- risks relating to different regulatory regimes in different jurisdictions; and
- risks relating to evolving and uncertain regulatory regimes.

The Company's future growth will depend substantially on its ability to address these, and other risks described in this section and in its other continuous disclosure materials available on SEDAR and on the Company's website. If it does not successfully address these risks, its business may be significantly adversely affected.

Managing growth

In order to manage growth and change in strategy effectively, the Company must: (a) maintain adequate systems to meet customer demand; (b) expand sales and marketing, distribution capabilities and administrative functions; (c) expand the skills and capabilities of its current management team; and (d) attract and retain qualified employees. The inability of the Company to deal with this growth may have a material adverse effect on its business, financial condition, results of operations and prospects.

Competition

Due to the nature of the Company's proprietary delivery system and the multiple barriers of entry, the Company has very few competitors in the nutraceutical and pharmaceutical industries in which the Company operates, the Company anticipates very little initial competition from large, well-trenched industry competitors. As well, because of the early stage of the cannabis industry in which the Company will operate, the Company expects to have very limited competition from new entrants. To become and remain competitive, the Company will continue its research and development, marketing, sales and support. The Company does not currently have sufficient resources to finance all of the research and development, marketing and sales support efforts which may be required to gain significant market penetration in each of its vertical markets. The inability to remain competitive as the product lines mature could materially affect the business, financial condition and results of operations of the Company.

Retention, acquisition and integration of skilled personnel

The loss of any member of the Company's management team could have a material adverse effect on its business and results of operations. In addition, the inability to hire new personnel and the increased costs of hiring new personnel could have a material adverse effect on the Company's business and operating results.

At present and for the near future, the Company will depend upon a relatively small number of key employees to develop, market, sell and support its products. The expansion of marketing and sales of its products will require the Company to find, hire and retain additional capable employees who can understand, explain, market and sell its products. There is intense competition for capable personnel and the Company may not be successful in attracting, training, integrating, motivating or retaining new personnel, vendors, or subcontractors for these required functions. New employees often require significant training and, in many cases, take significant time before they achieve full productivity. As a result, the Company may incur significant costs to attract and retain employees, including significant expenditures related to salaries and benefits and compensation expenses related to equity awards, and may lose new employees to its competitors or other companies before it realizes the benefit of its investment in recruiting and training them. In addition, as the Company moves into new jurisdictions, it will need to attract and recruit skilled employees in those areas.

Legal proceedings

From time to time, the Company may be a party to legal and regulatory proceedings, including matters involving governmental agencies, entities with whom it does business and other proceedings arising in the ordinary course of business. The Company will evaluate its exposure to these legal and regulatory proceedings and, where appropriate, establish reserves for the estimated liabilities in accordance with International Financial Reporting Standards. Assessing and predicting the outcome of these matters involves substantial uncertainties. Unexpected outcomes in these legal proceedings, or changes in management's evaluations or predictions and accompanying changes in established reserves, could have an adverse impact on the Company's financial results.

Regulatory compliance risks

Achievement of the Company's business objectives is contingent, in part, upon compliance with regulatory requirements enacted by governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost to operate its business. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by local governmental authorities. The impact of the compliance regime, any delays in obtaining, or failure to obtain or keep the regulatory approvals may significantly delay or impact the development of markets, products and sales initiatives and could have a material adverse effect on the business, results of operations and financial condition of the Company.

The Company will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment or remedial actions.

The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the Company's operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Reliance on securing and maintaining agreements with licensed partners.

The Company must secure service agreements with licensees that have obtained the requisite licenses with the appropriate regulatory authorities in the targeted jurisdictions to grow, store and sell cannabis products ("Licensees"). The failure of a Licensee to comply with the requirements of their license or to maintain their license would have a material adverse impact on the business, financial condition and operating results of the Company. There can be no guarantee that the applicable licenses will be maintained by Licensees or granted to other prospective Licensees in the future.

Product liability

As a distributor of products designed to be consumed by humans, the Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused damage, loss or injury. In addition, the sale of the Company's products involves the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Adverse reactions resulting from human consumption of the Company's products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that the

Company's products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning health risks, possible side effects or interactions with other substances.

A product liability claim or regulatory action against the Company could: i) result in increased costs; ii) adversely affect the Company's reputation with its Licensed Partners and consumers generally; and iii) have a material adverse effect on the results of operations and financial condition of the Company. There can be no assurance that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company's potential products.

Intellectual property

The Company has certain proprietary intellectual property, including but not limited to brands, trademarks, trade names, patent applications and proprietary processes. The Company relies on this intellectual property, know-how and other proprietary information, and generally requires employees, consultants and suppliers to sign confidentiality agreements. The company requires all customers, partners and organizations that receive any materials from the Company to sign a Material Transfer Agreement acknowledging the Intellectual property confidentiality, Company ownership and authorized usage. However, any confidentiality agreement may be breached, and the Company may not have adequate remedies for such breaches. Third parties may independently develop substantially equivalent proprietary information without infringing upon any of the Company's proprietary technology. Third parties may otherwise gain access to the Company's proprietary information and adopt it in a competitive manner. Any loss of intellectual property protection may have a material adverse effect on the Company's business, results of operations or prospects.

Unfavourable publicity or consumer perception

The success of the Company's products may be significantly influenced by the public's perception of marijuana's medicinal applications. Medical marijuana is a controversial topic, and there is no guarantee that future scientific research, publicity, regulations, medical opinion and public opinion relating to medical marijuana will be favourable. The medical marijuana industry is an early-stage business that is constantly evolving with no guarantee of viability. The market for medical marijuana is uncertain, and any adverse or negative publicity, scientific research, limiting regulations, medical opinion and public opinion relating to the consumption of medical marijuana may have a material adverse effect on our operational results, consumer base and financial results.

Consumer acceptance

There can be no assurance that the Company will develop any product that will be met with widespread consumer acceptance. Both new and established products fail to generate consumer interest on a regular basis. There is no assurance that the Company's products will be successfully adopted by consumers at one time or will still be in demand in the future. If the Company cannot develop and sell products in commercial quantities, the Company's current strategy will fail.

Insurance coverage

The Company's insurance coverage includes policies covering general liability, product liability, errors and omissions, marine cargo and property/machinery insurance.

The Company's production is, in general, subject to different risks and hazards, including adverse weather conditions, fires, other natural phenomena, industrial accidents, labour disputes, changes in the legal and regulatory framework applicable to the Company and environmental contingencies. Although management of the Company believes that the events and amounts of liability covered by its insurance policies will be reasonable, considering the risks relevant to its business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Company may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Company's financial resources, results of operations and prospects could be adversely affected.

Due to the number and size of claims against companies involved in the cannabis industry, a number of insurers providing directors and officers liability insurance ("D&O") have decided not to insure businesses operating in the Company's sector. On December 23, 2019, the Company's insurer gave notice that they would not renew the Company's D&O policy due to the fact the insurer is exiting the sector generally and the Company's policy expired on February 21 2020. The Company is working with its insurance broker to secure a new insurer; however, there is no assurance that the Company will be able to secure D&O coverage at a reasonable price.

Product recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labelling disclosure. If any of the Company's products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall, remedial action and any legal proceedings that might arise in connection with the recall.

The Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if the Company is subject to recall, the image of the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the Company's products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company's operations by regulatory agencies, requiring further management attention, potential loss of applicable licenses and potential legal fees and other expenses.

Limited avenues to market and promote products

To be successful, the Company's business must be successfully marketed. The market for the Company's products and services has and is expected to grow significantly and may require substantial sales and marketing capability. The Company will be dependent on independent parties to market its products and services. There can be no assurance that the Company can continue to market or can enter into satisfactory arrangements with third parties to continue to market its products and services in a manner that would assure its growth and acceptance in the marketplace.

Global economy

Financial markets are influenced by the economic and market conditions in other countries, including the United States and other global markets. Although economic conditions in these countries may differ significantly from economic conditions in Canada, investor reactions to developments in these other countries may substantially affect the capital flows into and the market value of securities of issuers with operations in the United States and Canada.

Access to capital

In executing its business plan, the Company makes, and will continue to make, substantial investments and other expenditures related to acquisitions, research and development and marketing initiatives. Since its formation, the Company has financed these expenditures through equity offerings. The Company will have further capital requirements and other expenditures as it proceeds to expand its business and/or take advantage of opportunities for acquisitions or other business opportunities that may be presented to it. The Company may incur major unanticipated liabilities or expenses. The Company can provide no assurance that it will be able to obtain financing to meet its growth needs.

Foreign sales and currency risks

The Company's functional currency is denominated in Canadian dollars. The Company currently expects future sales will be denominated in Canadian and U.S. dollars and may, in the future, have sales denominated in the currencies of additional countries. In addition, the Company incurs the majority of its operating expenses in Canadian dollars. In the future, the proportion of the Company's sales that are international are expected to increase. Such sales may be subject to unexpected regulatory requirements and other barriers. Any fluctuation in the exchange rates of foreign currencies may negatively impact the Company's business, financial condition and results of operations. The Company has not previously engaged in foreign currency hedging. If the Company decides to hedge its foreign currency exposure, it may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets. In addition, those activities may be limited in the protection they provide the Company from foreign currency fluctuations and can themselves result in losses.

Tax risks

The Company will operate and will be subject to income tax and other forms of taxation (which are not based upon income) in multiple tax jurisdictions. Taxation laws and rates which determine taxation expenses may vary significantly in different jurisdictions, and legislation governing taxation laws and rates is also subject to change. Therefore, the Company's earnings may be impacted by changes in the proportion of earnings taxed in different jurisdictions, changes in taxation rates, changes in estimates of liabilities and changes in the amount of other forms of taxation. The Company may have exposure to greater than anticipated tax liabilities or expenses.

The Company will be subject to income taxes and non-income taxes in a variety of jurisdictions and its tax structure is subject to review by both domestic and foreign taxation authorities and the determination of the Company's provision for income taxes and other tax liabilities will require significant judgment.

Repatriation of profits

As a company holding the stock of operating subsidiaries in other jurisdictions, it is anticipated that a significant amount of the Company's funds will be generated by the Company's operating subsidiaries. The Company's subsidiaries are subject to the requirements of various regulatory bodies, both domestically and internationally. Accordingly, if the Company's operating subsidiaries are unable, due to regulatory restrictions or otherwise, to pay dividends and make other payments to the Company when needed, the Company August be unable to satisfy the Company's obligations when they arise.

Off Balance Sheet Arrangements

The Company does not utilize off-balance sheet arrangements.

Change in accounting standards

Standards, Amendments, and Interpretations Issued but not yet Adopted

The IASB has issued several new standards and amendments that will be effective on various dates.

Standards issued and not yet adopted

Certain new standards, amendments, and interpretations to existing IFRS standards have been published but are not yet effective and have not been adopted early by the Company. Management anticipates that pronouncements will be adopted in the Company's accounting policy for the first period beginning after the effective date of the pronouncement. Information on new standards, amendments, and interpretations is provided below.

In January 2020, the IASB issued an amendment to IAS 1, Presentation of Financial Statements ("IAS 1") to clarify its requirements for the presentation of liabilities in the statement of financial position. The limited scope amendment affected only the presentation of liabilities in the statement of financial position and not the amount or timing of its recognition. The amendment clarified that the classification of liabilities as current or non-current is based on rights that are in existence at the end of the reporting period and specified that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability.

It also introduced a definition of 'settlement' to make clear that settlement refers to the transfer to the counterparty of cash, equity instruments, other assets or services. On October 31, 2022, the IASB issued Non-Current Liabilities with Covenants (Amendments to IAS 1). These amendments specify that covenants to be complied with after the reporting date do not affect the classification of debt as current or non-current at the reporting date. The amendment is effective for annual reporting periods beginning on or after January 1, 2024.

Standards issued and adopted

In February 2021, the IASB issued narrow-scope amendments to IAS 1, IFRS Practice Statement 2, Making Materiality Judgements and IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors. The amendments require the disclosure of material accounting policy information rather than disclosing significant accounting policies and clarified how to distinguish changes in accounting policies from changes in accounting estimates. Beginning Mar 1, 2023, the Company adopted the amendments. The adoption of the amendments did not have a material impact on the Annual Financial Statements.

Selected Financial Information

(For the three-month period ended May 31, 2024, and May 31, 2023)

The following tables show selected financial information for the three-month period ended and as at May 31, 2024 compared to the year ended February 29, 2024 and the three-month period ended May 31, 2023. The selected financial information set out below may not be indicative of the Company's future performance. The information contained in each table should be read in conjunction with the Company's Consolidated Financial Statements and related notes.

All amounts in \$,000

Summary Information	As at May 31, 2024	As at February 29, 2024	As at May 31, 2023
(Expressed in thousands of Canadian dollars – audited)	\$	\$	\$
Current assets	691	679	394
Non-current assets	1,124	1,206	1680
Total assets	1,815	1,885	2074
Current liabilities	2,875	2,918	5117
Non-current liabilities	2,246	2,124	194
Revenue	399	1,020	241
Net loss	1,256	4,306	567
Shareholders' equity (deficiency)	(3,306)	(3,158)	(3,237)

Discussion of Operations for the three-month period ended May 31, 2024 (in \$,000s)

For the three-month period ended May 31, 2024 the Company reported a net comprehensive loss of \$1,324 or \$0.01 per share compared to a net comprehensive loss of \$567 for the three-month period ended May 31, 2023.

The Company has added new cannabis customer accounts during the three-month period ended which generated first time revenue of \$96. Sales for the quarter to Aurora increased year over year to \$165 (2023- \$85). Service contract revenue of USD\$90 was unchanged from one year earlier.

Profit margins on the sale of cannabis strips increased year over year due to pricing of products new customers averaging 100% pricing increase over prior year products. In addition, price increases of 100% were implemented after the quarter end for both cannabis products and contract services customers.

Non-cash expenses increased in the first quarter for stock compensation from the issuance of options to directors, employees and advisors and accretion expenses for related party and convertible debts.

Revenue and gross profit

Segmented information

The Company has one operating segment comprising production, distribution, research, and the provision of technical services for the delivery of oral thin film strips containing active ingredients.

Entity-wide disclosure:

The Company has four primary sources of revenue:

- 1) Sales of health and wellness products consisting of nutraceuticals and xylitol;
- 2) Sales of oral thin film strips containing active ingredients under cannabis licensing;
- 3) Consulting services provided for the application of active ingredients with the Company's oral thin film polymer formulation and processes.

The following table sets out the revenue and costs for each revenue source:

Segmented Information	Three-month period ended May 31, 2024			Three-month period ended May 31, 2023		
	Revenue	Cost of Sales	Gross Profit	Revenue	Cost of Sales	Gross Profit
	\$	\$	\$	\$	\$	\$
Health and wellness	13,190	15,750	(2,560)	16,507	5,265	11,242
White Label	256,044	61,547	194,497	97,880	50,405	47,475
Product Testing	7,360	3,493	3,867	4,600	7,017	(2,417)
White Label	263,404	65,040	198,364	102,480	57,422	45,058
Services revenue	122,400	61,500	60,900	121,800	60,495	61,305
Total	398,994	142,290	256,704	240,787	123,182	117,605

Customer Concentration:

Three customers comprise 90% of total revenue during the three-month period ended May 31, 2024. Two comprised 95% (2023 – 95%) of White Label revenue during the three-month period year ended May 31, 2023. One customer comprised 100% (2023 – 100%) of licensing and consulting revenue.

Geographic Information:

All of the Company's operations and assets are in Canada.

Financial results

The following Table provides a more detailed break-down of the Company's financial results for the three-month period ended May 31, 2024 compared to the year ended May 31, 2023:

	Three-month period ended May 31 2024	Three-month period ended May 31 2023
(expressed in thousands of Canadian dollars - unaudited)	\$	\$
Revenue	398,994	240,787
Cost of sales	(142,290)	(123,182)
Gross Profit	256,704	117,605
Operating Expenses		
Personnel	356,970	325,365
Stock-based compensation	426,700	-
General and administrative	86,076	16,867
Sales and marketing	228,962	94,030
Research and development	29,516	22,080
Depreciation	82,733	146,512
Interest	304,033	79,632
Total operating expenses	1,514,990	684,486
Loss from Operations	(1,258,286)	(566,881)
Other Income (Loss) and (expenses):		
Foreign exchange gain (loss)	1,435	-
Net Income (Loss) before other comprehensive loss	(1,256,851)	(566,881)

The comparative losses reflect the following:

Expenses

(expressed in CDN\$000's)

Stock based compensation on the vested portion of the 2,500,000 share options granted to directors amounted to \$41 (2024 - \$nil). Share purchase options totaling 9,050,000 were issued to employees and advisors on April, 2024 resulting in a charge to share compensation expense of \$386.

General and administrative – Professional fees incurred in the first quarter of fiscal year 2025 (\$39) were incurred for share issue costs in conjunction with the private placement financing and accordingly have been included in the calculation of the common shares and warrants valuation rather than legal fees expense. In 2024 the Company incurred legal costs \$60k in connection with the filing and revocation of the cease order and the resumption of trading on the Canadian Securities Exchange.

Sales and marketing – The Company engaged third party marketing and advertising services in order to begin promoting the Company's products through social media channels.

Depreciation of \$83 (2024- \$627) consists of depreciation of property and equipment. In 2024, the depreciation expense of \$146 included the amortization of the right of use asset.

Right of use assets are fully amortized as a result of the expiry of the related premises lease on March 31, 2024. As a result occupancy costs included in General & Administrative expense increased by \$59 reflecting charge for two months of the monthly interest and principal amounts previously applied against the payment of the lease.

Interest - costs of \$304 (2024 - \$79) reflect both the increase in company borrowing costs of \$168 (2024 - \$nil) through the issue of convertible notes and the accretion expense of \$136 (2024 - \$nil) resulting from the inclusion of equity instruments in the convertible notes and related party debt private placements.

Summary of Quarterly Results

The following table provides a comparison of the results for each of the previous eight quarters:

(expressed in thousands of dollars)	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
	31-Aug	30-Nov	28-Feb	31-May	31-Aug	30-Nov	28-Feb	31-May
	CY2022	CY2022	CY2023	CY2023	CY2023	CY2023	CY2024	CY2024
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue:	133	305	218	241	353	233	193	399
Net Loss:	(914)	(583)	(2,181)	(566)	(730)	(981)	(2,843)	(1,256)
Per share loss	(0.04)	(0.01)	(0.01)	(0.005)	(0.01)	(0.01)	(0.02)	(0.01)

Liquidity and Capital Resources

As the Company is an early-stage company and has just started to generate revenue, the Company has financed its operations with equity and debt financing. The Company moved from start up to product manufacture and commercialization during the fourth quarter of the year ended February 28, 2021. As at May 31, 2024 the loss from operations and working capital deficiencies limits the Company's ability to fund its operations.

During the three-month period ended May 31, 2024, the Company accessed working capital financing of \$660,000 through a private placement offering which closed on May 30, 2024. Proceeds from the private placement were used to cover its operating costs during the first quarter of the 2025 fiscal year.

In May 2024, the Company completed a private placement common share financing totaling \$660,000 that provided the Company with the necessary working capital to operate throughout the first quarter of the fiscal year in accordance with its fiscal year 2025 business plan.

In June 2024, the Company completed a private placement common share financing totaling \$660,000 that provided the Company with the necessary working capital to operate throughout the first quarter of the fiscal year in accordance with its fiscal year 2025 business plan.

In the event the Company's plans change, its assumptions change or prove inaccurate, or its capital resources in addition to projected cash flow, if any, prove to be insufficient to fund operations, the Company may be required to seek additional financing. There can be no assurance that the Company will have sufficient financing to meet its future capital requirements or that additional financing will be available on terms acceptable to the Company.

The following table details the current assets and liabilities which comprise the work capital deficiency:

	\$
Working capital breakdown:	113,062
Cash and cash equivalents	236,173
Amounts receivable	152,201
Inventory	189,963
Prepaid expenses	113,062
Total current assets	691,399
Less:	
Accounts payable and accrued liabilities	2,548,719
Due to a related party	229,216
Unsecured convertible note	97,186
Total current liabilities	2,875,121
Working capital deficiency	(2,183,722)

For the three-month period ended May 31, 2024, the Company had an average monthly cash burn rate of approximately \$250,000 (2023 - \$175,000). For the year ended February 28 2024, the Company had an average monthly cash burn rate of approximately \$275,000 (FY2023 - \$225,000). The Company conserved cash through managing payment terms for accounts payable during the year and the completion of a shares for debt settlement offering on January 15, 2024 of \$699,618.

The Company is addressing its liquidity requirements as a vital component of its product development strategies. The Company requires access to sufficient financial resources to finance its vaccine program, its development of market awareness for its nutraceutical product lines and for managing its ongoing operations which are building a sustainable revenue stream through white label manufacturing. The Company has previously utilized private placement financing for serving its liquidity requirements.

The pharmaceutical vertical relationship has been initiated with Skycare Compounding. Skycare's co-development of OTF strips containing active pharmaceutical ingredients has enabled the Company to accelerate pharma product development utilizing its existing equipment and technical expertise with resulting cost control and minimized cost outlays. The products under development can be sold into the Canadian medical marketplace through Skycare providing a source of revenue for the Company with cost control. This strategy of leveraging its technology with strategic partners enables the Company to accelerate access to markets it could not enter without significant financing. The analysis of the Canadian market for the products under development indicate the need and size of the market can generate sufficient sales volumes in the early stages of the selling cycle to enable the Company to access its market acceptance and potential for further penetration and scale up of pharma-based products.

The Company has received significant international interest in its vaccine development programs. In May 2022 the Company was asked to participate in a global program at the 6th UNECE International Public-Private Partnerships (PPP) Forum and was shortlisted as one of the top four finalists of the UNECE entries. The submission centered on equitable access to medicines, vaccines, and nutritional supplements, with a particular emphasis on childhood immunization, which is key to reducing infectious disease-related morbidity and mortality in developing countries. UNECE recognized the development of the Company's proprietary, temperature and humidity-stable, oral thin film technology, QuickStrip™ - which can be used for vaccines, pharmaceutical and nutraceutical products - and the Company's aim to widen access to health and wellness products across the world.

The health and wellness vertical was impacted during the first quarter of fiscal year 2025 by delays in receiving goods being from foreign suppliers, resulting in missing the timelines for customers' fall product launch programs. Marketing costs for supporting the health and wellness product lines in Canada are budgeted at \$300,000 for the 2025 fiscal year. The expenditures are conditional on obtaining sufficient financing from external sources to

support the marketing programs. The Company is currently exploring strategic relationships with Canadian enterprises which can mitigate the Company's outlay for marketing costs and provide expertise in the delivery of health and wellness products to the Canadian consumer market.

The Company has also entered into a product development agreement with an international company with access to international markets for the delivery of products currently undergoing formulation development and market acceptance testing. A strategic agreement to provide OTF strips utilizing the requested active ingredients would include access to the necessary working capital to finance roll out of the program.

The Company's primary operating costs are personnel and occupancy, both utilized in the White Label manufacturing vertical. The Company does not yet produce and sell sufficient quantities to attain a level of profitability required to support the licensing and costs structure for the cannabis product vertical. With the termination of the MSS agreements originally entered into in 2019, the Company focused in fiscal year 2024 with the development of the in-manufacturing alternatives in order to prove the capability of the OTF manufacturing process developed by the Company. The Company has applied for Ontario Cannabis Stores (OCS) product approvals to sell its own brands through the highly regulated Ontario cannabis retail outlets. A successful application would enable the Company to begin rolling out its own products in the third quarter of this FY2024. The success and sustainability of the OTF formulation and production processes evidenced by the quality of the products produced and sold, provide the Company with the capability of access liquidity for the business in three ways:

- 1) Further penetration of the market in Canada through direct selling;
- 2) Entering into MSS agreements for the licence to use the Company's technology and equipment for international markets;
- 3) Monetization of the Canadian cannabis vertical through a strategic partnership or outright sale of the division to a Canadian licensed producer.

Each of these alternatives form part of the decision making regarding the Company's liquidity and access to financial resources in the 2025 fiscal year.

The Company is currently reliant on short term financing with maturities occurring in the fiscal year 2025. There is no assurance that the loans can be rolled over. The Company may be unable to meet its obligations to repay all or some portion of the loans without replacement financing. Access to capital markets is required by the Company during fiscal 2025 in order to provide the Company with sufficient financing alternatives.

On July 19, 2024, the Company closed a first tranche of an equity private placement financing raising \$309,000, through issuing common shares at \$0.17 per share. The equity private placement intends to raise \$6,000,000 through the issuance of common shares at the \$0.17 price. The private placement offering extends to August 8, 2024.

The Company has financing available through the issue of 29,166,393 warrants (16,922,225 warrants at \$0.14 and 16,336,357 at \$0.20) issued during the 2024 fiscal year in connection with its equity and convertible note financing. The Company 2,500,000 stock options to non-management directors on February 23, 2024 at an exercise price of \$0.15 per common share and 9,050,000 options to management and advisors on April 1, 2024 at an exercise price of \$0.18 per common share.

Promoters

Mark Upsdell was considered a promoter of the Company in 2018 by having taken the initiative in substantially reorganizing the business of the Company in connection with its amalgamation and reverse takeover transaction which resulted in the Company's common shares listing on the Canadian Securities Exchange. Mark Upsdell continues to be a promoter of the Company due to his continued involvement in the governance and management of the Company and his shareholdings in the Company. Mr. Upsdell is currently a director as well as the Chief Executive Officer and President of the Company and owns 12,553,825 common shares of the Company representing approximately 10% of its issued and outstanding shares including common shares issued for the payment of interest and fees on the convertible note amounting to 500,000. Mr. Upsdell also holds 1,500,000 stock options exercisable at \$0.18 per share, issued on April 1, 2024.

Pursuant to an employment agreement between the Company and Mark Upsdell for his services as Chief Executive Officer and President of the Company, Mr. Upsdell is compensated at the rate of \$300,000 annually. During the Covid-19 pandemic, Mr. Upsdell agreed to temporarily waive a portion of his compensation in order to conserve the Company's cash resources and his base salary was accordingly set at \$150,000. Depending on

the Company's financial position going forward, Mr. Upsdell's base salary may return to the amount entitled under his employment agreement.

Changes in key management personnel

Date	Change
February 7, 2024	Angela O'Leary was appointed a Director to the Board of Directors of the Company
September 18, 2023	Andrew Duckman resigned as Director from the Board of Directors
August 1, 2023	Andrew Duckman, Christine Hrudka and Marissa Cornacchia were appointed Directors to the Board of Directors of the Company
April 14, 2023	John McKimm was appointed a Director to the Board of Directors of the Company
April 14, 2023	Jason Lewis resigned as Director from the Board of Directors
March 19, 2022	Thomas Bryson's employment contract with the Company ended on March 19, 2024 and was not renewed.
March 19, 2022	Thomas Bryson was appointed President of Rapid Dose Therapeutics Corp.
August 13, 2020	Peter Thilo Hasler was appointed as a director.
August 29, 2020	Ken Fox resigned as a director.
February 28, 2020	Doug Hyland was named interim Chief Financial Officer ("CFO") to hold the position until such time as a replacement CFO was appointed.
February 20, 2020	Donald Sheldon resigned as a director and Miles Nagamatsu resigned as Chief Financial Officer.

Advisory Board

There are members on the Company's Advisory Board.

Rodney Butt MSc MBA

Rod is a Global Prescription Product Development Professional with more than thirty years experience in defining strategic options to bring unique products through the Clinical/Regulatory requirements. Rod coordinates the Company's Research and development projects with research, institutional and pharmaceutical collaborators on the Company's product development efforts.

Dr. Rick Tytus

Dr. Tytus is an Associate Clinical Professor in the Department of Family Medicine at McMaster University and co-founder of Banty, a virtual medical video platform. He has a proven track record working with innovative approaches that enhance a patient's interaction with health care providers. Dr. Tytus is the Chair for District Four of the Ontario Medical Association (OMA) and an active member of the National Virtual Care Task Force. Previously, Dr. Tytus served on the Board for the OMA, is Past-Chair of OntarioMD, and Past President of the Hamilton Academy of Medicine. Dr Tytus is a well-respected member of the medical community and a leader in medical education.

Dr. Glogauer

Dr. Glogauer is the Dentist in Chief at the University Health Network and Princess Margaret Cancer Centre and a Full Professor in the Faculty of Dentistry at the University of Toronto. His keen interest in research makes Dr. Glogauer the ideal Scientific Director at the Centre for Advanced Dental Research and Care at Mt. Sinai Hospital and the Chief Scientific Officer and Founder of Ostia Sciences Inc.

The Advisory Board has been constituted to provide guidance to management and the Board of Directors regarding strategic initiatives relating to the development of the Company's intellectual properties. Advisory Board members are eligible for Share Purchase Options granted pursuant to the Company's Stock Option Plan.

On December 15, 2021, 250,000 share purchase options were issued at \$0.55 per share vesting semi-annually over two years and expiring on December 15, 2026. On January 5, 2022 200,000 share purchase options were issued at \$0.51 per share vesting semi-annually over two years and expiring on January 5, 2027. The options were cancelled on February 28, 2024 and replaced with options at the option price of \$0.18 on April 1, 2024.

Statement of Corporate Governance

National Instrument 58-101: *Disclosure of Corporate Governance Practices* ("NI 58-101") requires the Company to disclose, on an annual basis, its approach to corporate governance with reference to the governance guidelines provided in National Policy 58-201: *Corporate Governance Guidelines* ("NP 58- 201").

The Company has reviewed its corporate governance practices under the guidelines contained in NP 58- 201. The Company's practices comply generally with the guidelines; however, the Board considers that some of the guidelines are not suitable for the Company at its current state of development and therefore the Company's governance practices do not reflect these particular guidelines. Set out below is a description of the Company's corporate governance practices as required to be disclosed by NI 58-101.

Board of Directors

As of the date of this MD&A, the Board is comprised of six directors. Mark Upsdell is not independent because of being the Chief Executive Officer of RDT. John McKimm is not independent, as the owner of Madison Corporate Partners, a secured lender to the Company.

Directorships

None of the directors is currently a director of any other issuers that are reporting issuers (or the equivalent) in a jurisdiction in Canada or abroad.

Orientation and Continuing Education

Changes to the Board are infrequent so there is no need for a formal orientation program for directors. The Board does not provide formal continuing education for directors. Directors of RDT maintain the skill and knowledge necessary to meet their obligations as directors through a combination of their existing education, experience as businesspersons and managers, professional continuing education requirements, service as directors of other issuers and advice from RDT's legal counsel, auditor and other advisers.

The Company does not offer a formal orientation and education program for new directors. The new directors familiarize themselves with the Company by speaking to other directors and by reading documents provided by the executive officers.

Ethical Business Conduct

The Company has adopted a Code of Business Conduct and Ethics (the "**Code**"). The Code provides guidance on the conduct of the Company's business and sets out the principles and procedures to be adhered to by the Company's Directors, officers, employees and consultants.

Directors and officers of RDT are expected to disclose dealings in the industry in which RDT operates. They are also subject to the general obligation under corporate law to declare and fully disclose any conflict of interest, refrain from participating in any discussion and not vote on any material contract or transaction with RDT in which the applicable director or officer has an interest. Accordingly, any such related party contract or transaction would require approval of the directors who are independent of the contract or transaction or, if there is no director who is independent of the contract or transaction, shareholder approval or ratification.

The Board monitors the ethical conduct of the Company and its management and ensures that it complies with applicable legal and regulatory requirements.

Nomination of Directors

RDT does not have a formal process or committee for proposing new nominees to the Board.

Compensation

Given RDT's current size and stage of development, its Board has not appointed a compensation committee and, accordingly, its Board as a whole is responsible for determining the compensation (including long-term incentives in the form of stock options) to be granted to RDT's executive officers (including the chief executive officer) and directors to ensure that such arrangements reflect the responsibilities and risks associated with each position. Management directors are required to abstain from voting in respect of their own compensation, thereby providing any independent members of the Board with considerable input as to executive compensation.

The Board relies on the knowledge and experience of its members to set appropriate levels of compensation for executive officers. Neither the Company nor the Board currently has any contractual arrangement with any executive compensation consultant. The Board reviews and makes determinations with respect to executive

officer compensation on an *ad hoc* basis. When determining executive officers' compensation, the Board reviews the performance of executive officers based on their achievements during the preceding year.

The Board uses all the data available to it to ensure that the Company is maintaining a level of compensation that is both commensurate with the size of the Company and sufficient to retain key personnel. In reviewing comparative data, the Board does not engage in benchmarking for the purpose of establishing compensation levels relative to any predetermined level and does not compare its compensation to a specific peer group of companies. In the Board's view, external data provides insight into external competitiveness, but it is not an appropriate single basis for establishing compensation levels. External data is considered, along with an assessment of individual performance and experience, the Company's business strategy, and general economic considerations.

Board Committees

The standing committees of the Board are:

- 1) Governance and Compensation Committee, chaired by Christine Hrudka; and
- 2) Audit Committee, chaired by John McKimm.

Assessments

The Board has responsibility for assessing the effectiveness of the Board as a whole, and the contribution of individual directors. Due to the small size of the Board, no formal process is in place. Shareholders have the ultimate authority to determine whether to re-elect the current directors or to elect one or more replacement directors.

The directors, the Board and its committees are assessed on an ongoing basis by reviewing their respective attendance and performance. The Board expects to establish a formal assessment process in the future.

The directors, the Board and its committees are assessed on an ongoing basis by reviewing their respective attendance and performance. The Board expects to establish a formal assessment process in the future.

On behalf of the Board of Board of Directors, thank you for your continued support:

“Mark Upsdell”

Mark Upsdell, CEO